HLS Therapeutics Inc.
HLS Therapeutics Inc. (HLTRF) Financial Performance & Income Statement Overview
Analyze HLS Therapeutics Inc. (HLTRF) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
HLS Therapeutics Inc. (HLTRF) Income Statement & Financial Overview
View the income breakdown for HLS Therapeutics Inc. HLTRF across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $12.62M | $15.54M | $14.09M | $14.52M |
| Cost of Revenue | $2.40M | $2.69M | $2.23M | $8.16M |
| Gross Profit | $10.22M | $12.86M | $11.85M | $6.36M |
| Gross Profit Ratio | $0.81 | $0.83 | $0.84 | $0.44 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $5.62M | $6.18M | $6.80M | $6.96M |
| Operating Expenses | $12.42M | $15.90M | $16.75M | $6.96M |
| Total Costs & Expenses | $14.81M | $18.58M | $18.99M | $10.69M |
| Interest Income | $32000.00 | $34984.00 | $49394.00 | $97000.00 |
| Interest Expense | $2.02M | $2.30M | $2.45M | $2.71M |
| Depreciation & Amortization | $5.36M | $5.43M | $5.51M | $5.86M |
| EBITDA | $2.92M | $4.79M | $3.06M | $3.83M |
| EBITDA Ratio | $0.23 | $0.31 | $0.22 | $0.26 |
| Operating Income | -$2.19M | -$3.04M | -$4.90M | $3.83M |
| Operating Income Ratio | -$0.17 | -$0.20 | -$0.35 | $0.26 |
| Other Income/Expenses (Net) | -$2.27M | $102000.00 | -$3.03M | -$5.44M |
| Income Before Tax | -$4.46M | -$2.94M | -$4.90M | -$1.61M |
| Income Before Tax Ratio | -$0.35 | -$0.19 | -$0.35 | -$0.11 |
| Income Tax Expense | -$23000.00 | $85000.00 | -$59000.00 | $4.08M |
| Net Income | -$4.44M | -$3.02M | -$4.84M | -$5.68M |
| Net Income Ratio | -$0.35 | -$0.19 | -$0.34 | -$0.39 |
| EPS | -$0.14 | -$0.09 | -$0.15 | -$0.18 |
| Diluted EPS | -$0.14 | -$0.09 | -$0.15 | -$0.18 |
| Weighted Avg Shares Outstanding | $31.79M | $31.79M | $31.79M | $31.83M |
| Weighted Avg Shares Outstanding (Diluted) | $31.79M | $31.79M | $31.79M | $31.83M |
Financial performance has remained strong, with revenue growing from $14.52M in Q2 2024 to $12.62M in Q1 2025. Gross profit continued to perform well, with margins at 81% in the latest quarter. Operating income reached -$2.19M in Q1 2025, holding a steady -17% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $2.92M. Net income dropped to -$4.44M, keeping EPS at -$0.14. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan